biguanides has been researched along with HIV Coinfection in 5 studies
Biguanides: Derivatives of biguanide (the structure formula HN(C(NH)NH2)2) that are primarily used as oral HYPOGLYCEMIC AGENTS for the treatment of DIABETES MELLITUS, TYPE 2 and PREDIABETES.
biguanides : A class of oral hypoglycemic drugs used for diabetes mellitus or prediabetes treatment. They have a structure based on the 2-carbamimidoylguanidine skeleton.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Although formulated NB325 appeared generally safe for application in these studies, the low but observable level of toxicity suggests the need for improvements in the compound and/or formulation." | 1.37 | Cervicovaginal safety of the formulated, biguanide-based human immunodeficiency virus type 1 (HIV-1) inhibitor NB325 in a murine model. ( Kish-Catalone, T; Krebs, FC; Labib, M; Lozenski, K; Pirrone, V; Rando, RF; Wigdahl, B, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wilkinson, RA | 1 |
| Pincus, SH | 1 |
| Song, K | 1 |
| Shepard, JB | 1 |
| Weaver, AJ | 1 |
| Labib, ME | 2 |
| Teintze, M | 1 |
| Thakkar, N | 2 |
| Pirrone, V | 3 |
| Passic, S | 2 |
| Zhu, W | 3 |
| Kholodovych, V | 3 |
| Welsh, W | 3 |
| Rando, RF | 2 |
| Wigdahl, B | 4 |
| Krebs, FC | 4 |
| Keogan, S | 1 |
| Rando, R | 2 |
| Labib, M | 3 |
| Passic, SR | 1 |
| Ferguson, ML | 1 |
| Catalone, BJ | 1 |
| Kish-Catalone, T | 2 |
| Howett, MK | 1 |
| Lozenski, K | 1 |
5 other studies available for biguanides and HIV Coinfection
| Article | Year |
|---|---|
Improved guanide compounds which bind the CXCR4 co-receptor and inhibit HIV-1 infection.
Topics: Anti-HIV Agents; Biguanides; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; HIV In | 2013 |
Specific interactions between the viral coreceptor CXCR4 and the biguanide-based compound NB325 mediate inhibition of human immunodeficiency virus type 1 infection.
Topics: Anti-HIV Agents; Biguanides; Binding, Competitive; CD3 Complex; CD4-Positive T-Lymphocytes; Cell Lin | 2009 |
Persistent interactions between biguanide-based compound NB325 and CXCR4 result in prolonged inhibition of human immunodeficiency virus type 1 infection.
Topics: Antiviral Agents; Biguanides; CD4-Positive T-Lymphocytes; Cells, Cultured; Chemotaxis, Leukocyte; Ep | 2010 |
Structure-activity relationships of polybiguanides with activity against human immunodeficiency virus type 1.
Topics: Animals; Anti-HIV Agents; Anti-Infective Agents; Biguanides; Cell Line; Dose-Response Relationship, | 2010 |
Cervicovaginal safety of the formulated, biguanide-based human immunodeficiency virus type 1 (HIV-1) inhibitor NB325 in a murine model.
Topics: Administration, Intravaginal; Animals; Anti-HIV Agents; Biguanides; Disease Models, Animal; Drug-Rel | 2011 |